Literature DB >> 9175299

The double-blind test of sodium hyaluronate (ARTZ) on osteoarthritis knee.

J J Wu1, L Y Shih, H C Hsu, T H Chen.   

Abstract

BACKGROUND: At this time, no definite treatment exists for osteoarthritis disease. Hyaluronate (ARTZ) is one of the most important components of synovial fluid. It is generally accepted that hyaluronic acid protects the articular cartilage and soft tissue surfaces from trauma during joint function.
METHODS: Ninety patients with 116 knees diagnosed as early arthritis (mild to moderate) by four senior orthopaedic surgeons were selected to join this study. The trial design was applied with a double-blind model. The selected patients were randomly injected with 2.5 ml drugs (ARTZ or placebo) intra-articularly once a week for five consecutive weeks without the use of local anesthetic drugs. Evaluation results included grading of subjective and objective symptoms and daily activities. The follow-up period was up to six months after initial injection.
RESULTS: According to the results of clinical evaluation and statistical analysis, SPH (ARTZ) is quite effective for osteoarthritis knees, and significantly better than the placebo. The effective peak was one week after five injections of ARTZ. The effective period could last up to three months without additional treatment. The efficacy of ARTZ on osteoarthritis knees was more prominent for relief of motion pain and improvement of knee movement. No side effects developed during a six month period.
CONCLUSIONS: Based on clinical results here, SPH is a safe drug for administration as an alternative approach to treat the osteoarthritis knee.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175299

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi (Taipei)        ISSN: 0578-1337


  21 in total

Review 1.  Evidence-based knee injections for the management of arthritis.

Authors:  Olivia T Cheng; Dmitri Souzdalnitski; Bruce Vrooman; Jianguo Cheng
Journal:  Pain Med       Date:  2012-05-23       Impact factor: 3.750

2.  Local application of hyaluronan gel in conjunction with periodontal surgery: a randomized controlled trial.

Authors:  Karim M Fawzy El-Sayed; Moushira A Dahaba; Shadw Aboul-Ela; Mona S Darhous
Journal:  Clin Oral Investig       Date:  2011-10-20       Impact factor: 3.573

Review 3.  Effectiveness and utility of hyaluronic acid in osteoarthritis.

Authors:  Alberto Migliore; Simone Procopio
Journal:  Clin Cases Miner Bone Metab       Date:  2015 Jan-Apr

Review 4.  The role of intra-articular hyaluronan (Sinovial) in the treatment of osteoarthritis.

Authors:  Antonio Gigante; Leonardo Callegari
Journal:  Rheumatol Int       Date:  2010-11-28       Impact factor: 2.631

Review 5.  Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis.

Authors:  Jasmin Arrich; Franz Piribauer; Philipp Mad; Daniela Schmid; Klaus Klaushofer; Marcus Müllner
Journal:  CMAJ       Date:  2005-04-12       Impact factor: 8.262

Review 6.  Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2010-11-01       Impact factor: 3.923

Review 7.  Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature.

Authors:  Anita Aggarwal; Ian P Sempowski
Journal:  Can Fam Physician       Date:  2004-02       Impact factor: 3.275

8.  Safety of Repeated Injections of Sodium Hyaluronate (SUPARTZ) for Knee Osteoarthritis: A Systematic Review and Meta-Analysis.

Authors:  Raveendhara R Bannuru; Christopher R Brodie; Matthew C Sullivan; Timothy E McAlindon
Journal:  Cartilage       Date:  2016-04-11       Impact factor: 4.634

Review 9.  Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications.

Authors:  David D Waddell
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Post-Hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteria.

Authors:  Erol Onel; Kathleen Kolsun; Jeffrey I Kauffman
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.